Preventing herpes outbreaks in autoimmune rheumatic diseases
Treatments studied
Part of Infections, Skin clinical trials.
This trial tests whether a medicine called acyclovir can prevent herpes simplex outbreaks in people who also have an autoimmune rheumatic disease. It may help reduce the number of painful cold sores or genital herpes episodes you experience.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older.
- You have been diagnosed with an autoimmune rheumatic disease (such as rheumatoid arthritis, lupus, or others listed below).
- A blood test shows you have had a herpes simplex infection in the past (titer of 1:8 or higher).
- You have had at least 4 cold sores or genital herpes outbreaks in the last 12 months.
- You are not allergic to acyclovir or any part of the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the recombinant shingles vaccine in adults with autoimmune rheumatic diseases who are on certain mild medications. It aims to see if the vaccine is safe and effective for them.
This trial tests whether Shingrix (a shingles vaccine) is safe and works well in adults with rheumatic or immune-related conditions. It compares Shingrix to a placebo (inactive shot) to see how well it prevents shingles and affects immune symptoms.
This trial tests whether 2LHERP® can reduce or manage frequent herpes infections around the mouth. It compares the study drug to a placebo (inactive treatment) in people who get many episodes each year.
This Phase 2 study tests whether repeat doses of UB-621 can make frequent genital herpes outbreaks safer and less frequent. It may help people who have HSV-2 and many recurrences each year.
This trial tests whether acyclovir, an antiviral drug, can help patients with pneumonia who are on breathing support and have herpes simplex virus in their lung fluid. The goal is to see if it improves recovery.
This study tests a new mRNA vaccine designed to protect against herpes simplex virus type 2 (HSV-2), the virus that causes genital herpes. It is for healthy adults who have not had a genital herpes outbreak in the last 6 months.
Hear when a new Autoimmune Rheumatic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.